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Abstract
Background: FABP4 is predominantly expressed in adipose tissue, and its circulating levels are linked with obesity and a
poor atherogenic profile.
Objective: In patients with a wide BMI range, we analyze FABP4 expression in adipose and hepatic tissues in the settings of
obesity and insulin resistance. Associations between FABP4 expression in adipose tissue and the FABP4 plasma level as well
as the main adipogenic and lipolytic genes expressed in adipose tissue were also analyzed.
Methods: The expression of several lipogenic, lipolytic, PPAR family and FABP family genes was analyzed by real time PCR.
FABP4 protein expression in total adipose tissues and its fractions were determined by western blot.
Results: In obesity FABP4 expression was down-regulated (at both mRNA and protein levels), with its levels mainly predicted
by ATGL and inversely by the HOMA-IR index. The BMI appeared as the only determinant of the FABP4 variation in both
adipose tissue depots. FABP4 plasma levels showed a significant progressive increase according to BMI but no association
was detected between FABP4 circulating levels and SAT or VAT FABP4 gene expression. The gene expression of FABP1,
FABP4 and FABP5 in hepatic tissue was significantly higher in tissue from the obese IR patients compared to the non-IR
group.
Conclusion: The inverse pattern in FABP4 expression between adipose and hepatic tissue observed in morbid obese
patients, regarding the IR context, suggests that both tissues may act in a balanced manner. These differences may help us
to understand the discrepancies between circulating plasma levels and adipose tissue expression in obesity.
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Introduction
Cytoplasmic fatty-acid-binding proteins (FABPs) are proteins
with a tissue-specific distribution implicated in cellular uptake and
transport of fatty acids as well as coordination of metabolic and
inflammatory pathways and modulation of gene expression [1,2].
FABP4 is highly expressed in adipose tissue and also expressed in
macrophages; it is one of the most abundant proteins in mature
adipocytes [3] and is also detected at high concentrations in
human serum [4,5]. Although the biological role of FABP4 is not
yet well understood, its function has been linked to insulin
sensitivity, lipid metabolism and inflammation [6]. Recently,
FABP4 has emerged as an important mediator in the crosstalk
between adipocytes and macrophages in adipose tissue. Animal
studies have shown that FABP4 knock-out mice are protected from
the development of obesity-induced IR, impaired glucose toler-
ance and atherosclerosis, and their adipocytes have reduced
lipolysis effectiveness [7,8]. FABP4 2/2 mice in an apo E 2/2
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background show delayed development of arteriosclerotic plaques
[9].
Others studies have shown that FABP4 plasma concentrations
are increased in patients with obesity, metabolic syndrome (MS),
type 2 diabetes (T2D), familial combined hyperlipidemia, lipodys-
trophy syndromes and cardiovascular disease [10–15]. Moreover,
there is an increasing evidence based on population studies
supporting the predictive role of increased serum FABP4 for MS
and cardiometabolic risk. In cross-sectional studies including
overweight or moderately obese patients, FABP4 was closely
associated with obesity and MS [5,16]. Furthermore, in others
prospective studies FABP4 levels are considered an early marker of
metabolic risk for metabolic syndrome development and T2D
[4,17,18]. These findings suggest that circulating FABP4 could
promote inflammation, mediate insulin resistance, type 2 diabetes
and atherosclerosis. In addition, FABP4 could be a potential target
for treating metabolic diseases [19].
On the other hand, metabolic and functional differences
between adipose tissue depots (subcutaneous (SAT) and visceral
(VAT)) may be determinant in the development of obesity and
related disorders [20,21]. Some differences in lipogenic, lipolytic
and adipokine gene profiles between the two depots have been
reported in human studies [22]. Furthermore, several studies have
shown a higher gene expression of FABP4 in the SAT than in the
VAT of obese subjects [23,24]. However, other authors failed to
find a significant difference between FABP4 gene expression in
SAT and VAT [25]. In a recent study that we have carried out, we
have found that FABP4 gene expression was significantly lower in
the morbidly obese group than in obese and lean subjects in the
VAT and in the SAT [26]. However, no data are yet available
about FABP4 concerning both adipose tissue depots and the liver.
More recently, targeted deletion of certain FABPs in murine
models has revealed that FABP4 and FABP5 deficient mice are
protected against diet-induced obesity, insulin resistance, type 2
diabetes, and a fatty liver, implying that these proteins may play a
role in regulating liver fat [27].
We hypothesized that FABP4 may have an important role in
the metabolic balance of the adipose and liver tissue in obesity.
The aim of this study was to analyze the FABP4 expression in
paired samples of SAT and VAT and hepatic tissues in the context
of obesity and IR in patients with a wide BMI range. We also
determined the possible relationships between the SAT and VAT
FABP4 expression and the FABP4 plasma level as well as the main
adipogenic and lipolytic genes expressed in adipose tissue.
Methods and Procedures
Ethics Statement
Human samples. Appropriate Institutional Review Board
approval and adequate Biobank written informed consent were
obtained from all the participants. The ethics committees of the
corresponding hospitals (Joan XXIII University Hospital (Tarra-
gona, Spain) and Virgen de la Victoria Hospital (Malaga, Spain)
reviewed and approved the experimental protocols.
Animal samples. All animal studies were conducted in
accordance with the ethical guidelines for the care and use of
laboratory animals of the National Institutes of Health. The
protocol was approved by the ethics committee of the Virgen de la
Victoria Hospital (Malaga, Spain).
Processing and Selection of Human Study Samples
Between January 2010 and January 2011, two hundred forty-
eight subjects were assessed by the endocrinology and surgery
departments at Joan XXIII University Hospital (Tarragona,
Spain) and Virgen de la Victoria Hospital (Malaga, Spain). All
patients who met the inclusion criteria were recruited to carry out
this study. Bio-banking samples included total adipose tissue from
subcutaneous and visceral origin, liver tissue, serum and plasma.
All the patients had fasted overnight, at least 12 hours before the
surgical procedure. Blood samples were collected before the
surgical procedure from the antecubital vein, 20 ml of blood with
EDTA (1 mg/ml) and 10 ml of blood in silicone tubes. 15 ml of
collected blood was used for plasma separation. Plasma and serum
samples were stored at 280uC until analytical measurements were
performed. EDTA collected blood was used to determine HbA1c.
VAT and SAT samples from the same individual were obtained
during the surgical procedure. Adipose tissue samples were
collected and washed in PBS 1X, immediately frozen in liquid
nitrogen and stored at 280uC.
Samples were selected according to stratification by age, gender
and BMI (categorized using the World Health Organization
criteria) [28]. A first cohort of 62 subjects with a body mass index
(BMI) range of 19.82 to 38.54 Kg/m2 recruited before cholecys-
tectomy or surgery for abdominal hernia was selected from the
Joan XXIII University Hospital biobank. A second cohort of 12
lean subjects (BMI ,25) recruited before cholecystectomy and 40
morbidly obese subjects recruited before bariatric surgery were
selected for the study from the Virgen de la Victoria Hospital
biobank. The morbidly obese subjects were stratified according to
their IR index (HOMA-IR) as high-grade IR (MO-IR; HOMA-
IR.8,) or non IR (MO non-IR; HOMA-IR,4.7). The cut-off
point for the HOMA-IR was taken from previous studies carried
out in a healthy population with no carbohydrate metabolism
disorders [29].
All the subjects were of Caucasian origin and reported that their
body weight had been stable for at least 3 months before the study.
They had no systemic disease other than obesity, and all had been
free of any infections during the month before the study. Primary
cardiovascular disease, arthritis, acute inflammatory disease and
renal diseases were specifically excluded by biochemical work-up.
Patients on lipid-lowering drugs were excluded from this study.
Smoking habits and alcohol consumption were measured using a
standardized questionnaire. All the experiments described below
were performed blindly.
Anthropometric Measurements
The height was measured to the nearest 0.5 cm and the body
weight to the nearest 0.1 kg. The BMI was calculated as weight
(kilograms) divided by height (metres) squared. The waist
circumference was measured midway between the lowest rib
margin and the iliac crest [30].
Adipose Tissue Sampling and RNA Extraction
Biopsy samples of VAT (omental) and SAT (anterior abdominal
wall) were obtained from all subjects. Samples were obtained
during abdominal elective surgical procedures (cholecystectomy,
surgery for abdominal hernia or during bariatric surgery). The
biopsy samples were washed in physiological saline and immedi-
ately frozen in liquid nitrogen. The biopsy samples were
maintained at 280uC until analysis. Total RNA isolation from
adipose tissues was obtained using RNeasy Lipid Tissue Mini Kit
(Qiagen GmbH, Germany) and treated with DNase (RNase-free
DNase Set; Qiagen). The RNA concentration was determined by
absorbance at 260 nm (A260), and the purity was estimated by
determining the A260/A280 ratio with a Nanodrop spectropho-
tometer (Nanodrop Technologies, Wilmington, DE). The integrity
of total purified RNA was checked by denaturing agarose gel
electrophoresis and ethidium bromide staining.
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Liver Biopsy and Total RNA Extraction
In the morbidly obese cohort, wedge biopsies (10–400 mg) were
taken when necessary during the bariatric procedure for
histopathological assessment. Seventeen biopsies were available
for the study. The samples were immediately frozen and stored at
280uC. Frozen tissue samples (200–300 mg) were homogenized in
1 ml of Tripure isolation reagent and RNA extraction was done
following the manufacturer’s instructions (Roche Applied Science).
The RNA concentration and purity were determined in the same
way as explained for the adipose tissue above.
Adipose Tissue Fractionation
Fresh adipose tissue was finely diced into small pieces (10–
30 mg), washed in PBS and incubated in Medium 199 (Gibco)
plus 4% BSA and 2 mg/mL of collagenase Type I (Sigma-Aldrich)
for 1 h in a shaking water bath at 37uC. Mature adipocytes were
separated by filtration through a 200mm mesh fabric (Spectrum
Laboratories, Rancho Domı´nguez, CA, USA) and by centrifuga-
tion for 5 min at 1500 g. The mature adipocytes were removed
from the top layer and the pellet consisted of stromovascular cells.
Cells were washed 4 times in PBS. Total RNA from isolated
adipocytes and from the stromovascular fraction (SVF) was
extracted as in [31].
Analytical Methods
Serum glucose, cholesterol, HDL cholesterol, triglycerides
(Randox Laboratories Ltd., Antrium, UK) and free fatty acids
(FFA) (Wako Bioproducts, Richmond, VA, USA) were measured
using standard enzymatic methods. Low-density lipoprotein
(LDL) cholesterol was calculated using the Friedewald formula.
The insulin was analyzed using an immunoradiometric assay
(IRMA) (BioSource International, Camarillo, CA, USA), show-
ing a 0.3% cross-reaction with proinsulin. The intra- and inter-
assay CV were 1.9% and 6.3%, respectively. The homeostasis
model assessment of insulin resistance (HOMA-IR index) was
determined as glucose (mmol/L) x insulin (mIU/L)]/22.5 [16].
Plasma FABP4 levels were measured by sandwich enzyme-
linked immunosorbent assay (BioVendor Laboratory Medicine,
Inc Palackeho, Czech Republic). The sensitivity was 0.2 ng/mL.
The intra- and inter-assay coefficients of variation were 5.8%
and 14.7%, respectively.
Gene Expression Relative Quantification in Human
Samples
For first-strand cDNA synthesis, a constant amount of 1 mg of
total RNA was reverse transcribed using random hexamers as
primers and Transcriptor Reverse Transcriptase (Roche, Mann-
heim, Germany). mRNA levels were assessed by real-time PCR
using an Applied Biosystems 7500 Fast Real-Time PCR System
(Applied Biosystems, Darmstadt, Germany) with TaqMan tech-
nology. The reaction was performed, following the manufacturer’s
protocol, in a final volume of 25 ml. The cycle program consisted
of an initial denaturing of 10 min at 95uC, then 40 cycles of 15-s
denaturing phase at 95uC, and 1 min annealing and extension
phase at 60uC. The commercially available and prevalidated
TaqMan primer/probe sets used for human samples were as
follows: GAPDH (4326317E, RefSeq. NM_002046.3) and b-Actin
(4352935E, RefSeq. NM_001101.2) used as endogenous controls
for the target gene in each reaction of samples from liver and
adipose tissue, respectively. We analyzed the mRNA expression
levels in SAT and VAT of peroxisome proliferator-activated
receptors (PPARa, (Hs00947539_m1, RefSeq NM_001001928.2),
PPARd (Hs00234592_m1, RefSeq NM_005037.5) and PPARc
(Hs00234592_m1, RefSeq NM_138712); hormone-sensitive lipase
(HSL) (Hs00193510_m1, RefSeq NM_005357); adipose triglycer-
ide lipase (ATGL) (Hs00386101_m1, RefSeq NM_020376); acyl-
CoA synthetase short-chain family member 2 (ACSS2)
(Hs01120921_g1 RefSeq NM_001242393.1); CD36 molecule
(CD36) (Hs01567185_m1, RefSeq NM_000072.3); Adiponectin
(APM) (Hs00605917_m1 RefSeq NM_004797); diacylglycerol-O-
acyltransferase 1 (DGAT1) (Hs01017541_m1, RefSeq
NM_012079.4); diacylglycerol-O-acyltransferase 2 (DGAT2)
(Hs01045913_m1, RefSeq NM_032564.3) and perilipin
(PLIN)(Hs01106925_m1, RefSeq NM_001145311.1); fatty acid-
binding protein 1, 4 and 5, (FABP4 (Hs01086177_m1, RefSeq.
NM_001442.2), FABP5 (Hs02339439_g1, RefSeq. NM_001444.1)
and FABP1 (Hs00155026_m1, RefSeq. NM_001443.1)). In liver
samples we only analyzed the mRNA levels of FABP 1, 4 and 5. In
the isolated adipocytes and SVF we analyzed the mRNA level of
FABP4. A threshold cycle (Ct value) was obtained for each
amplification curve and a DCt value was first calculated by
subtracting the Ct value for the corresponding endogenous control
cDNA from the Ct value for each sample and transcript. Fold
changes compared with the endogenous control were then
determined by calculating 22DCt, and expression results are given
as the expression ratio relative to GAPDH or b-Actin gene
expression, according to the manufacturer’s guidelines. All samples
were quantified in duplicate and positive and negative controls
were included in all the reactions.
Western Blot Assays
Total proteins from adipose tissue samples were extracted by
NE-PER Nuclear and Cytoplasmic Extraction Reagents proto-
col (Pierce). Protein extracts (30 mg) were separated by SDS-
PAGE, blotted onto a PVDF membrane and then incubated
with anti-human FABP4 antibody at 1:1000 dilution (Santa
Cruz Biotechnology, CA, USA) and developed with Super-
SignalH West Femto/Pico Maximum Sensitivity Substrate
(Pierce, Rockford, IL, USA). Protein signals were visualized by
electrochemiluminescence using Quantity OneH software (Bio-
Rad Laboratories). Data were normalized to the corresponding
b-actin band intensities.
Immunofluorescence
Five-micron sections of frozen adipose tissue were fixed with
paraformaldehyde 4%. Staining was performed overnight at 4uC
with anti FABP4 antibody at 1:200 dilution, and anti CD68 at
1:25 dilution, washed, and visualized using AF546 and AF488
antibodies at 1:500 dilution (Molecular Probes Inc, OR, USA),
respectively. As a negative control, the entire immunofluorescence
procedure was performed in the absence of primary antibody. The
slides were counterstained with DAPI.
Immunohistochemistry
Sections of formalin-fixed paraffin-embedded adipose tissue
were deparaffinised and rehydrated prior to antigen unmasking
by boiling in 1 mM EDTA, pH 8. Sections were blocked in
normal serum and incubated overnight with anti-human FABP4
antibody at 1:200 dilution, and anti CD68 (Santa Cruz
Biotechnology) at 1:25 dilution. Secondary antibody staining
was performed using the VECTASTAIN ABC kit (Vector
laboratories, Inc. Burlingame, CA) and detected with diamino-
benzidine (DAB, Vector Laboratories). Sections were counter-
stained with haematoxylin prior to dehydration and coverslip
placement. As a negative control, the entire immunohistochem-
ical procedure was performed on adjacent sections in the
absence of primary antibody.
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Studies in Animals
Adult wild-type mice (WT) (8 males and 8 females) and ob/ob
mice (8 males and 8 females) C57BL6 were purchased from
Jackson Laboratory (The Jackson Laboratory, Bar Harbor, ME).
All mice were housed under standard housing conditions on a 12-h
light/dark cycle in humidity and temperature-controlled rooms
(22uC) and fed ad libitum standard chow diet (RM3, with 11.5%
of calories from fat; SDS, Essex, U.K.) during two weeks. The
animals were killed after 12 hours of fasting and VAT and liver
samples were immediately excised, frozen in liquid nitrogen and
stored at 280uC until its analysis.
RNA Extraction and Gene Expression Relative
Quantification in Animal Samples
The RNA isolation from VAT and liver tissue and the posterior
gene expression analysis by real-time PCR in these mice samples
were carried out as described above for the human samples. The
commercially available and pre-validated TaqMan primer/probe
sets used for real-time PCR were as follows: GAPDH (4352339E;
RefSeq. NM_008084.2) and b-Actin (4352341E; RefSeq.
NM_007393.1) as endogenous controls for the target gene in
each reaction of samples from liver and adipose tissue, respec-
tively, FABP4 (Mm00445880_m1, RefSeq. NM_024406.2) and
FABP1 (Mm00444340_m1, RefSeq. NM_017399.4).
Statistical analysis. Statistical analysis was performed by
using the SPSS software v.15 (SPSS, Chicago, IL). Normal
distributed data are expressed as mean values (standard
deviation, SD), and variables with a non-Gaussian distribution
are expressed as median (InterQuartil Range, IQR). Discrete
variables are expressed as frequency. For statistical analysis of
expression variables that did not have a Gaussian distribution,
values were logarithmically transformed or analyzed by non-
parametrical tests. Differences between more than two groups
were compared by using ANOVA with a post hoc Bonferroni
correction. Differences between depots were analyzed by the
Wilcoxon nonparametric test with a Post-hoc Bonferroni correc-
tion. Differences between groups according to smoking and
alcohol consumption status were analyzed using the chi-square
test. The Mann-Whitney U test was used to determine the
differences in the VAT and SAT FABP4 expression levels
between smokers and non-smokers as well as between alcohol
consumers and no alcohol consumers. Post hoc calculation
showed that the selected sample size for the cohort 1 and the
cohort 2 had a 98% and 97% power respectively for detecting a
Table 1. Characteristics of the population, circulating FABP4 levels and FABP4 expression levels in cohort 1.
Cohort 1
Lean Overweight Obese
BMI,25 25#BMI,30 30#BMI,35
n=19 n=28 n=15
Age (years) 51.7616.0 57.1615.0 57.4612.8
Gender (male) 13 (68.4%) 16 (57.1%) 9 (60.0%)
BMI (kg/m2) 23.6 (22.1–24.2) 27.2 (26.5–27.9)* 32.1 (30.8–33.6)*#
Waist (cm) 83.0 (79.0–90.0) 97.0 (90.5–100.0)* 107.0 (100.0–117.2)*#
SBP (mmHg) 120 (120–127) 130 (121–140) 145 (130–160)*1
DBP (mmHg) 70 (60–80) 70 (70–80) 80 (78–90)"
Cholesterol (mM) 5.261.2 4.961.0 5.260.8
HDL-C (mM) 1.560.5 1.360.3 1.460.3
Triglycerides (mM) 1.0 (0.7–1.6) 1.1 (0.8–1.5) 1.0 (0.7–1.3)
Glucose (mM) 4.860.7 5.560.5* 5.660.5*
Insulin (mIU/ml) 3.4 (2.1–6.7) 4.0 (2.8–7.2) 6.6 (4.5–16.5)"
HOMA-IR 0.75 (0.54–1.8) 1.01 (0.52–2.09) 1.60 (1.19–4.79)"
Non-smokers 12 (63.1%) 17 (60.7%) 9 (60%)
Current-smokers 7 (36.8%) 11(39.3%) 6 (40%)
None-Alcohol consumption 13 (68.4%) 19 (67.8%) 10 (66.7%)
Alcohol consumptiona 6 (31.6%) 9 (32.1%) 5 (33.3%)
FABP4(ng/ml) 15.5 (12.2–23.1) 20.0 (15.6–32.9) 28.7 (21.5–44.7)"
SAT FABP4mRNA 1.64 (1.4–2.3) 1.36 (1.5–1.6)" 1.20 (0.9–1.8)"
VAT FABP4 mRNA 1.47 (0.6–1.8) 0.93 (0.1–1.4)* 1.47 (0.7–2.3)
BMI, body mass index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; HDL-C,
HDL cholesterol; HOMA-IR, Homeostasis model assessment of insulin resistance.
aAlcohol consumption was considered from 0.5–1 drink/day for women and 1–2 drinks/day for men.
Differences vs. Lean: *P,0.001;
"P,0.05. Differences vs. Overweight:
#P,0.001;
1P,0.05.
Differences vs. Obese: C, P,0.002. Data are expressed as mean and standard deviation (SD).
for normal variables or median and interquartile range (25th–75th) for non-normally distributed variables. Discrete variables are expressed as frequency.
doi:10.1371/journal.pone.0048605.t001
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significant difference (P,0.05) between FABP4 mRNA expres-
sion levels according to BMI distribution. Associations between
quantitative variables were evaluated by Pearson correlation
analysis or Spearman correlation for non-normally distributed
variables. The independence of the associations was evaluated
by linear regression analysis, adjusting for age and gender. In
the first cohort in the SAT and VAT depot, the BMI, HOMA-
IR index and mRNA expression of genes for lipid metabolism
(ATGL, PLIN, CD36, ACSS2, DGAT, HSL and FABP5 (only for
VAT depot)), adiponectin and PPARs were selected as indepen-
dent variables. At the same time, in the second cohort in both
adipose tissues, the BMI, plasma insulin, plasma triglyceride
levels and HOMA-IR were included as independent variables.
Statistical significance occurred if a computed two-tailed
probability value was P,0.05.
Results
The main clinical, anthropometrical and analytical character-
istics of the two study cohorts are shown in Table 1 and Table 2.
FABP4 Expression in Adipose Depots
SAT and VAT FABP4 mRNA expression levels were strongly
correlated between them (R = 0.453; P,0.001) (Table 3). In SAT,
lean subjects showed significantly higher mRNA FABP4 expres-
sion levels than overweight and obese subjects from cohort 1. This
trend was confirmed in the morbidly obese subjects from cohort 2.
In VAT, FABP4 expression levels showed a U-shaped curve, with
higher levels in lean and obese subjects when compared with the
overweight group (Table 1). When morbidly obese subjects were
analysed, a clear down-regulation in visceral fat was observed,
mainly in the MO-IR patients. There were no significant
differences in the SAT and VAT FABP4 expression levels between
smoking and non-smoking either in cohort 1 or cohort 2 (cohort 1:
P= 0.829 and P= 0.770 respectively; cohort 2: P= 0.725 and
P= 0.721 respectively). Likewise, alcohol consumption had no
significant effect on the SAT and VAT FABP4 mRNA levels
(cohort 1: P= 0.969 and P= 0.819; cohort 2: P= 0.480 and
P= 0.709, respectively). No association was detected between
circulating levels and subcutaneous or visceral FABP4 gene
expression. However, FABP4 plasma levels were positively
associated with VAT FABP5 gene expression (r = 0.465;
Table 2. Characteristics of the population, circulating FABP4
levels and FABP4 expression levels in cohort 2.
Cohort 2
Lean
Morbid no
IR Morbid IR
BMI,25 BMI.35 BMI.35
n=12 n=14 n=26
Age (years) 44.3611.3 41.8610.4 41.7613.8
Gender (male) 6 (50%) 4 (28.6%) 7 (26.9%)
BMI (kg/m2) 21.264.7 45.4610.3* 55.564.1*1
Waist (cm) 84.5611.4 118.1620.0* 140.3610.9*#
SBP (mmHg) 119614.9 133618.9" 147622.4*1
DBP (mmHg) 72615.7 82610.6 86617.0
Cholesterol (mM) 5.161.1 5.161.2 5.261.1
HDL-C (mM) 1.460.7 1.360.3 1.060.6
Triglycerides (mM) 1.160.8 1.560.9 1.3 (1.0–1.7)
Glucose (mM) 4.660.4 5.160.6" 5.760.9*
Insulin (mIU/ml) 3.762.5 11.764.5* 30.4613.4*#
HOMA-IR 0.9760.45 2.6260.92* 8.363.8*#
Non-smokers 9 (75%) 10 (71.4%) 19 (73%)
Current-smokers 3 (25%) 4 (28.6%) 7 (26.9%)
None- alcohol
consumption
8 (66.7%) 9 (64.3%) 17 (65.4%)
Alcohol consumptiona 4 (33.3%) 5 (35.7%) 9 (34.65)
FABP4(ng/ml) 14.9611.9 30.8610.1* 39.2611.5*1
SAT FABP4mRNA 2.260.8 1.660.6" 1.260.3*1
VAT FABP4 mRNA 2.060.9 1.860.9 1.360.8"
BMI, body mass index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood
Pressure; HDL-C,
HDL cholesterol; HOMA-IR, Homeostasis model assessment of insulin resistance.
aAlcohol consumption was considered from 0.5–1 drink/day for women and 1–2
drinks/day for men.
Differences vs. Lean: *P,0.001;
"P,0.05. Differences vs. Morbid no IR:
#P,0.001;
1P,0.05.
Differences vs. Morbid IR: C, P,0.002. Data are expressed as mean and standard
deviation (SD).
for normal variables or median and interquartile range (25th–75th) for non-
normally distributed variables. Discrete variables are expressed as frequency.
doi:10.1371/journal.pone.0048605.t002
Table 3. Bivariate correlations with FABP4 adipose tissue
gene expression in every depot and anthropometric and
metabolic characteristics in the first cohort.
SAT FABP4 VAT FABP4
R P value R P value
Population Characteristics
BMI 20.323 0.003 20.390 0.002
SBP 20.324 0.018 – –
HOMA-IR 20.285 0.023 20.332 0.030
Insulin 20.336 0.006 20.342 0.020
Gene expression
VAT FABP4 0.453 ,0.001 – –
Adiponectin 0.821 ,0.001 0.938 ,0.001
ATGL 0.357 ,0.001 0.715 ,0.001
CD36 0.676 ,0.001 0.861 ,0.001
ACSS2 0.512 ,0.001 0.526 ,0.001
DGAT1 0.238 ,0.033 0.691 ,0.001
DGAT2 – – 0.515 ,0.001
HSL 0.543 ,0.001 0.669 ,0.001
PLIN 0.434 ,0.001 0.808 ,0.001
PPARa 0.561 ,0.001 0.322 0.003
PPARc 0.661 ,0.001 0.798 ,0.001
FABP5 – – 0.478 ,0.001
R, Correlation coefficient. Significant differences P,0.05. BMI, body mass index;
SBP, Systolic Blood Pressure; HOMA-IR, Homeostasis model assessment of
insulin resistance; Peroxisome proliferator-activated receptors (PPARa, PPARd
and PPARc); hormone-sensitive lipase (HSL); adipose triglyceride lipase (ATGL);
acyl-CoA synthetase short-chain family member 2 (ACSS2); CD36 molecule
(CD36); Adiponectin (APM); diacylglycerol-O-acyltransferase 1 (DGAT1);
diacylglycerol-O-acyltransferase 2 (DGAT2) and perilipin (PLIN); fatty acid-
binding protein 1, 4 and 5 (FABP4, FABP5 and FABP1).
doi:10.1371/journal.pone.0048605.t003
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Figure 1. FABP4 expression is higher in isolated adipocytes (ADI) than in the stromovascular fraction (SVF). (A) FABP4 mRNA expression
levels in ADI and SVF from n = 15 subjects with paired adipose biopsies (ADI vs. SVF, *P= 0.001). Data are expressed as median and IQR. (B) FABP4
protein levels in total VAT, and in ADI and SVF fractions, from n = 4 subjects. Data are expressed as mean and SD. (ADI vs. SVF, " P,0.05) (C)
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P= 0.001). Furthermore, circulating FABP4 levels showed a
significant progressive increase according to BMI, with higher
levels in women and positively associated with BMI, blood
pressure, HOMA-IR and FFA (data not shown).
FABP4 mRNA/protein Expression in Total and Adipose
Tissue Fractions
A selected number of subjects ranging from lean to obese
phenotype were analysed for protein quantification. FABP4
protein levels in VAT tended to be lower than in SAT. However,
these differences did not reach statistical significance.
We examined whether FABP4 expression in human adipose
tissue was mainly due to mature adipocyte cells compared to other
cell types from the stromovascular pool. After fractioning fresh
adipose tissue, we observed that FABP4 mRNA was significantly
more expressed in the adipocyte fraction (Fig. 1A). Protein
expression was confirmed by Western blot analysis (Figs. 1B and
1C) immunofluorescence (Fig. 1D) and immunohistochemistry
(Fig. 1E), obtaining similar results to the mRNA expression study.
Thus, FABP4 protein was basically found in mature adipocytes
with a lower signal in the SVF. Immunohistochemical and
immunofluorescence staining confirmed that the majority of
FABP4 was localized in mature adipocytes. The signal obtained
in the SVF was mainly attributed to the macrophage content
surrounding the adipocytes, as was shown by CD68 co-localization
immunostaining and immunofluorescence (Figs. 1D and 1E).
Relationship between FABP4 Gene Expression and
Adipose Tissue Genes
Associations between SAT and VAT FABP4 expression levels
and genes related with lipid synthesis, FFA transport, lipolysis
regulation, lipases, PPAR transcription factor family, adiponectin and
FABP5 were analysed in the first cohort. The most significant
bivariate associations are shown in Table 3. In order to strengthen
the independence of these associations as predictors of FABP4
expression, a multiple regression analysis model was constructed
for each depot, including the above-mentioned bivariate correla-
tions, adjusting for age and gender. In the SAT depot model, BMI,
the HOMA-IR index and mRNA expression of SAT genes for
lipid metabolism (ATGL, PLIN, CD36, ACSS2, DGAT1 and HSL),
adiponectin and PPARs were selected as independent variables. The
result presented a multiple correlation coefficient (R) of 0.918, and
SAT FABP4 expression was mainly associated positively by ATGL
(B = 0.551; P,0.0001) and PPARa (B = 0.498; P= 0.001) gene
expression and inversely by the HOMA-IR index (B =20.062;
P= 0.033). In the VAT model, BMI, HOMA-IR and the gene
expression described above, including FABP5, were included as
independent variables. The model presented an R = 0.964 and
VAT FABP4 expression was mainly associated by adiponectin
(B = 0.302; P,0.0001), ATGL (B = 0.234; P= 0.027) and inversely
by the HOMA-IR index (B =20.023; P= 0.005).
Regarding the second morbidly obese cohort, a multiple linear
regression analysis was also carried out to weight the contribution of
the bivariate associations previously observed in the SAT and VAT
FABP4 gene expression. The equation was also adjusted for age and
gender. Thus, BMI, plasma insulin, plasma triglyceride levels and
HOMA-IR were included as independent variables. BMI appeared
as the only determinant, explaining nearly 50% of the FABP4
variation in both adipose tissue depots (B =20.384; P,0.0001 and
B =20.402; P= 0.002 in SAT and VAT, respectively).
FABP4 Expression in Liver
The mRNA expression of the FABP family (FABP1, FABP4 and
FABP5)wasanalysed in liverbiopsies fromasubgroupof themorbidly
obese cohort (Table 4). These subjects were representative of the
entire morbidly obese cohort and no differences regarding age,
gender or metabolic variables except for the insulin and HOMA-IR
index were observed between the groups. The MO-IR group showed
a significant higher FABP1, FABP4 and FABP5 mRNA expression
levels than the MO non-IR group (P,0.05) (Table 4).
FABP4 Expression in Adipose and Liver Tissues from
Animal Models
FABP4 gene expression in the VAT as well as FABP1 and
FABP4 mRNA level in the liver were analyzed in WT and ob/ob
mice subjected to fasting. We found a significantly greater FABP4
expression in the VAT depot in WT compared to ob/ob mice
(P,0.05). On the other hand, in the liver we found a significant
two-fold increase in FABP1 expression in WT compared to ob/ob
Representative blot of FABP4 protein in total VAT and SAT, and in ADI and SVF fractions. (D) Immunofluorescence detection of FABP4 (red) and CD68
(green) in VAT. The counterstaining of nuclei (DAPI) is shown in blue. Images are representative of VAT collected from five subjects. (E)
Immnunohistochemical detection of FABP4 (brown, right panel) and CD68 (macrophage-specific antigen, middle panel) and negative control (left
panel) in VAT. Images are representative of VAT sections collected from five subjects. A: Adipocyte; M: Macrophage. Arrow-heads indicate the specific
signal.
doi:10.1371/journal.pone.0048605.g001
Table 4. Anthropometric and biochemical characteristics and
mRNA expression of FABP1, FABP4 and FABP5 in a subgroup of
morbidly obese and morbidly obese IR patients with liver
biopsies.
Morbid no IR Morbid IR
n=7 n=10
Age (years) 43.4368.73 44.3068.26
Waist(cm) 123.78613.37 125.9069.87
Hip (cm) 140.5868.54 144.7569.17
BMI (Kg/m2 ) 41.7663.70 45.3666.47
SBP (mm Hg) 106.42620.75 114.24619.31
DBP (mm Hg) 91.42610.69 87.50611.36
Insulin (mIU/ml) 9.1562.16 25.1567.26*
Glucose (mM) 5.160.6 5.460.7
Cholesterol (mM) 5.4261.2 5.3762.1
Triglycerides (mM) 1.460.4 1.360.8
HDL-C (mM) 1.060.3 1.160.7
LDL-C (mM) 2.661.0 2.260.7
HOMA-IR 2.0960.54 6.0362.18*
FABP4 mRNA 0.7860.48 2.2861.27*
FABP1 mRNA 1.0160.20 1.6360.75*
FABP5 mRNA 0.2560.19 1.6561.28*
Data are mean 6 SD;
*indicates significant differences between the means of the two groups.
(P,0.05). BMI, body mass index; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol;
HOMA-IR, Homeostasis model assessment of insulin resistance; SBP, Systolic
Blood Pressure; DBP, Diastolic Blood Pressure.
doi:10.1371/journal.pone.0048605.t004
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mice (P,0.05). In contrast, the liver FABP4 mRNA gene
expression was significantly higher in ob/ob mice in comparison
with WT mice (Fig. 2).
Discussion
In this study we observed an inverse relationship between
FABP4 expression and obesity, with a greater down-regulation
with severe IR. Interestingly, FABP4 circulating levels did not
parallel adipose tissue expression. Moreover, the inverse pattern in
FABP4 gene expression observed between adipose and hepatic
tissues, regarding the IR context, suggests a complementary
regulatory system in which different tissues work in a balanced
manner.
Several studies have linked FABP4 circulating levels with obesity
and other diseases [32–36]. These associations suggested that
FABP4 may be involved in the vascular events related with these
pathologies [32]. Adipocytes are the main source of FABP4, and it
would be rational to think than a higher circulating plasma protein
levels, greater adipose tissue expression. However, our study
demonstrates an inverse association between obesity and FABP4
adipose tissue expression. These differences were confirmed in two
separate cohorts, strengthening the validity of the observation. A
previous study in morbidly obese women found no differences in
FABP4 adipose tissue expression when compared with lean
counterparts; however the low number of lean subjects included
may have contributed to the discrepancies [37]. Concerning
FABP4 circulating levels, our results failed to find an association
with adipose tissue expression.
Fisher et al., demonstrated that adipose tissue expression of
FABP4 was related to circulating non esterified fatty acid levels in
obese subjects, which would explain in part the insulin resistant
environment observed in obesity [7]. Adipose FABP4 interacts
physically with HSL promoting lipolysis [8]. In fact, we observed
that FABP4 expression was mainly determined by ATGL. VAT has
a greater lipolytic potential than SAT, and the release of FFA from
VAT directly into the portal circulation is one of the mechanisms
involved in fatty liver disease and hepatic IR [38].
Figure 2. FABP4 expression in adipose and liver tissues from mice. Fasting mRNA expression of FABP4 visceral adipose tissue in ob/ob
(n = 16) (grey bar) and WT (n = 16) (black bar) mouse. Adipose tissue expression level of the gene was normalized using b-actin. The results are given
as the mean 6 SD. *indicates significant differences between the means of the two groups (P,0.05). (B) Fasting mRNA expression levels of hepatic
FABP1 and FABP4 in ob/ob (n = 16) (grey bar) and WT (n = 16) (black bar) mouse. Hepatic tissue expression levels for each gene were normalized using
GADPH. The results are given as the mean6SD. *indicates significant differences between the means of the two groups (P,0.05).
doi:10.1371/journal.pone.0048605.g002
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Viewing the FABP4 mRNA down-regulation found in obese
patients, we are tempted to speculate about a possible adipose
tissue dysfunction leading to metabolic disorders. Thus, low
FABP4 expression in adipose tissue could lead to less FFA
transport to b-oxidation, resulting in a FFA accumulation, which
may exceed the adipose tissue storage capacity, resulting in excess
fat ‘‘overspilled’’ to non-adipose tissues such as the liver. In the
liver, the initial response is to facilitate the storage in the form of
triacylglycerides but the limited capacity becomes saturated. Lipid
excess produces toxic reactive species promoting lipotoxicity.
These data suggest that a high adipose tissue FABP4 expression
may have a protective role, controlling the availability of FFA and
their metabolites in the cytoplasm [39–41]. Of note, in our study
the adiponectin adipose tissue expression appeared as a positive
determinant of FABP4 expression, a protein with a predominant
role in insulin sensitivity with probable anti-inflammatory activity
in metabolic diseases. These results are in line with a recent report
in which data from DNA microarray-based gene expression
profiling showed a progressive down-regulation of genes involved
in fatty acid metabolism with increasing fat mass in patients with
the metabolic syndrome [42].
Insulin resistance emerged as an important determinant of
FABP4 adipose expression. Hence, when IR increased, FABP4
expression in adipose tissue decreased. This observation disagrees
with the data obtained in several animal studies. Thus, mouse
models with genetic disruption of FABP4 showed a significant
improvement in insulin sensitivity despite an increase in body
weight, highlighting this protein as an important player in IR
mechanisms. However, when the effect of FABP4 knockdown in
adipose tissue was studied, no effect on plasma glucose, insulin
sensitivity or lipid homeostasis was observed [43]. These
observations may help to explain the absence of increased FABP4
gene expression in our patients. A possible explanation has been
attributed in part to a compensatory expression increase of other
FABP proteins, such as FABP5 in adipose tissue. In fact, FABP5
mRNA was highly correlated with FABP4 mRNA in VAT, and
with FABP4 circulating levels, suggesting a possible co-regulatory
role between them. Unfortunately, we have no mechanistic studies
to unravel the intrinsic regulatory pathways involving IR and
FABP4 regulation in human adipose tissue, but the present data
suggest a positive effect of insulin-sensitivity on FABP4 expression.
We found an significant increased mRNA expression of FABP1,
FABP4 and FABP5 in the liver of morbidly obese-IR patients,
which contrasts with the significantly decreased expression of
FABP4 in adipose tissue that we found in the MO-IR patients
compared to lean controls. Therefore, we hypothesized that
decreased FABP4 expression in adipose tissue linked to obesity
could be compensated by an increased expression of FABP4 in
peripheral tissues with the onset of IR. Thus, this higher FABP4
expression found in the liver of MO-IR patients indicates that
FABP4 expression could be a predictor of IR in morbidly obese
patients. The same results were found in the animal model studied:
VAT FABP4 expression was also significantly lower in ob/ob mice
as compared with WT mice. However, when liver FABP4
expression was analyzed, we found a significant difference between
WT and ob/ob mice, with a more elevated hepatic FABP4 gene
expression in ob/ob mice than in WT mice.
One of the main limitations of our study is its cross-sectional
design, which does not permit to infer pathophysiological
mechanisms with the observed results. Thus, the obtained results
should be interpreted with caution. Moreover, we are aware that
the low number of subjects analyzed for protein data and the
absence of quantification of the in vivo fat mass depots hinder the
adequate interpretation of the findings. However, protein and
gene expression data were along the same lines. Another limitation
was the inability to analyze liver biopsies from lean healthy
subjects because of obvious ethical concerns. Finally, we have not
taken into account the possible effect of lifestyle factors such as the
changes in physical activity of the study subjects on the FABP4
plasma level, that previously have been described as the main
predictors of FABP4 plasma modifications even after adjusting for
body mass index and insulin resistance parameters.
In summary, we observed a decrease in FABP4 expression in
adipose tissue inversely associated with obesity, with the insulin-
resistance status being an important determinant involved in the
tissue expression. We also found an increased liver expression of
FABP4 in MO-IR patients, suggesting that adipose tissue and liver
may act in a balanced manner according to the insulin resistance
status. In conclusion, we propose that FABP4 may have different
roles when analysed systemically or locally. Thus, a more global
view is necessary to better understand its function. Further
prospective experiments are required to confirm these results.
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